288 related articles for article (PubMed ID: 34248970)
1. Circulating and Synovial Pentraxin-3 (PTX3) Expression Levels Correlate With Rheumatoid Arthritis Severity and Tissue Infiltration Independently of Conventional Treatments Response.
Boutet MA; Nerviani A; Lliso-Ribera G; Leone R; Sironi M; Hands R; Rivellese F; Del Prete A; Goldmann K; Lewis MJ; Mantovani A; Bottazzi B; Pitzalis C
Front Immunol; 2021; 12():686795. PubMed ID: 34248970
[TBL] [Abstract][Full Text] [Related]
2. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA).
Luchetti MM; Piccinini G; Mantovani A; Peri G; Matteucci C; Pomponio G; Fratini M; Fraticelli P; Sambo P; Di Loreto C; Doni A; Introna M; Gabrielli A
Clin Exp Immunol; 2000 Jan; 119(1):196-202. PubMed ID: 10606983
[TBL] [Abstract][Full Text] [Related]
3. Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies.
Weitoft T; Larsson A; Saxne T; Manivel VA; Lysholm J; Knight A; Rönnelid J
Scand J Rheumatol; 2017 Sep; 46(5):346-352. PubMed ID: 27973973
[TBL] [Abstract][Full Text] [Related]
4. Pentraxin 3 inhibits fibroblast growth factor 2 induced osteoclastogenesis in rheumatoid arthritis.
Zhao S; Wang Y; Hou L; Wang Y; Xu N; Zhang N
Biomed Pharmacother; 2020 Nov; 131():110628. PubMed ID: 32890968
[TBL] [Abstract][Full Text] [Related]
5. Acute phase reactant, Pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis.
Sharma A; Khan R; Gupta N; Sharma A; Zaheer MS; Abbas M; Khan SA
Clin Chim Acta; 2018 May; 480():65-70. PubMed ID: 29408170
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis.
Boutet MA; Nerviani A; Lliso-Ribera G; Lucchesi D; Prediletto E; Ghirardi GM; Goldmann K; Lewis M; Pitzalis C
Rheumatology (Oxford); 2020 Apr; 59(4):828-838. PubMed ID: 31504934
[TBL] [Abstract][Full Text] [Related]
7. Plasma pentraxin 3 is associated with progression of radiographic joint damage, but not carotid atherosclerosis, in female rheumatoid arthritis patients: 3-year prospective study.
Asanuma YF; Aizaki Y; Noma H; Yokota K; Matsuda M; Kozu N; Takebayashi Y; Nakatani H; Hasunuma T; Kawai S; Mimura T
Mod Rheumatol; 2020 Nov; 30(6):959-966. PubMed ID: 31615315
[No Abstract] [Full Text] [Related]
8. A decrease in galectin-1 (Gal-1) levels correlates with an increase in anti-Gal-1 antibodies at the synovial level in patients with rheumatoid arthritis.
Xibillé-Friedmann D; Bustos Rivera-Bahena C; Rojas-Serrano J; Burgos-Vargas R; Montiel-Hernández JL
Scand J Rheumatol; 2013; 42(2):102-7. PubMed ID: 23244209
[TBL] [Abstract][Full Text] [Related]
9. Pentraxin 3 is a marker of early joint inflammation in patients with juvenile idiopathic arthritis.
Padeh S; Farzam N; Chayen G; Gerstein M; Berkun Y
Immunol Res; 2013 Jul; 56(2-3):444-50. PubMed ID: 23579776
[TBL] [Abstract][Full Text] [Related]
10. Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Deyab G; Hokstad I; Whist JE; Småstuen MC; Agewall S; Lyberg T; Bottazzi B; Meroni PL; Leone R; Hjeltnes G; Hollan I
PLoS One; 2017; 12(2):e0169830. PubMed ID: 28225768
[TBL] [Abstract][Full Text] [Related]
11. Increased Circulating Pentraxin 3 Levels in Patients with Rheumatoid Arthritis: A Meta-analysis.
Guan SY; Chen Y; Shao M; Yang H; Xu W; Shuai Z; Zhao H; Zhao D; Pan F
Curr Pharm Des; 2022; 28(27):2260-2269. PubMed ID: 35708089
[TBL] [Abstract][Full Text] [Related]
12. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy -- a pilot study from the VErA cohort.
Lanfant-Weybel K; Michot C; Daveau R; Milliez PY; Auquit-Auckbur I; Fardellone P; Brazier M; Mejjad O; Daragon A; Krzanowska K; Jouen F; Tron F; Le Loarer F; Le Loët X; Vittecoq O
Joint Bone Spine; 2012 Dec; 79(6):574-80. PubMed ID: 22459417
[TBL] [Abstract][Full Text] [Related]
13. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.
Humby F; Lewis M; Ramamoorthi N; Hackney JA; Barnes MR; Bombardieri M; Setiadi AF; Kelly S; Bene F; DiCicco M; Riahi S; Rocher V; Ng N; Lazarou I; Hands R; van der Heijde D; Landewé RBM; van der Helm-van Mil A; Cauli A; McInnes I; Buckley CD; Choy EH; Taylor PC; Townsend MJ; Pitzalis C
Ann Rheum Dis; 2019 Jun; 78(6):761-772. PubMed ID: 30878974
[TBL] [Abstract][Full Text] [Related]
14. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
[TBL] [Abstract][Full Text] [Related]
15. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
[TBL] [Abstract][Full Text] [Related]
16. Serum amyloid A (SAA) induces pentraxin 3 (PTX3) production in rheumatoid synoviocytes.
Satomura K; Torigoshi T; Koga T; Maeda Y; Izumi Y; Jiuchi Y; Miyashita T; Yamasaki S; Kawakami A; Aiba Y; Nakamura M; Komori A; Sato J; Ishibashi H; Motokawa S; Migita K
Mod Rheumatol; 2013 Jan; 23(1):28-35. PubMed ID: 22447522
[TBL] [Abstract][Full Text] [Related]
17. Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis.
Zhang XP; Ma JD; Mo YQ; Jing J; Zheng DH; Chen LF; Wu T; Chen CT; Zhang Q; Zou YY; Lin JZ; Xu YH; Zou YW; Yang ZH; Ling L; Miossec P; Dai L
Front Immunol; 2021; 12():778480. PubMed ID: 34887865
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis.
Šenolt L; Šumová B; Jandová R; Hulejová H; Mann H; Pavelka K; Vencovský J; Filková M
PLoS One; 2015; 10(7):e0132674. PubMed ID: 26204444
[TBL] [Abstract][Full Text] [Related]
19. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
Hashimoto T; Yoshida K; Hashimoto N; Nakai A; Kaneshiro K; Suzuki K; Kawasaki Y; Shibanuma N; Hashiramoto A
Int J Rheum Dis; 2017 Jun; 20(6):722-730. PubMed ID: 27943573
[TBL] [Abstract][Full Text] [Related]
20. Identification of HBEGF+ fibroblasts in the remission of rheumatoid arthritis by integrating single-cell RNA sequencing datasets and bulk RNA sequencing datasets.
Chen N; Fan B; He Z; Yu X; Wang J
Arthritis Res Ther; 2022 Sep; 24(1):215. PubMed ID: 36068607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
